Lien Beckers1, Dieter Ory2, Ivana Geric1, Lieven Declercq2, Michel Koole3, Michael Kassiou4, Guy Bormans2, Myriam Baes5. 1. Department of Pharmaceutical and Pharmacological Sciences, Laboratory for Cell Metabolism, KU Leuven - University of Leuven, Campus Gasthuisberg O/N2, Herestraat 49, 3000, Leuven, Belgium. 2. Department of Pharmaceutical and Pharmacological Sciences, Laboratory for Radiopharmacy, KU Leuven - University of Leuven, Leuven, Belgium. 3. Department of Nuclear Medicine and Molecular Imaging, KU Leuven- University of Leuven, Leuven, Belgium. 4. School of Chemistry, The University of Sydney, Sydney, NSW, 2006, Australia. 5. Department of Pharmaceutical and Pharmacological Sciences, Laboratory for Cell Metabolism, KU Leuven - University of Leuven, Campus Gasthuisberg O/N2, Herestraat 49, 3000, Leuven, Belgium. Myriam.Baes@kuleuven.be.
Abstract
PURPOSE: Activation of the innate immune system plays a significant role in pathologies of the central nervous system (CNS). In order to follow disease progression and evaluate effectiveness of potential treatments involved in neuroinflammation, it is important to track neuroinflammatory markers in vivo longitudinally. The translocator protein (TSPO) is used as a target to image neuroinflammation as its expression is upregulated in reactive glial cells during CNS pathologies. However, it remains unclear in which microglial phenotypes TSPO levels are upregulated, as microglia can display a plethora of activation states that can be protective or detrimental to the CNS. PROCEDURES: We assessed the levels of TSPO transcripts in cultured microglia that were polarized into pro- and anti-inflammatory states in vitro and in the brain of mice in which an anti-inflammatory environment was induced in vivo. In addition, we used a mouse model of peroxisomal multifunctional protein-2 (MFP2) deficiency that exhibits widespread neuroinflammation despite no neuronal loss and monitored TSPO expression by immunohistochemistry and by imaging using the TSPO radiotracer [18F]DPA-714. RESULTS: TSPO expression was selectively increased in so-called classically activated or M1 microglia but not in alternatively activated or M2 microglia in vitro. In agreement, TSPO transcript levels were not induced in an anti-inflammatory brain environment. We found that both transcript and protein levels of TSPO are significantly increased in the brain of Mfp2 -/- compared to those of the control mice and TSPO immunoreactivity colocalized predominantly with microglia in Mfp2 -/- brain. In vitro and ex vivo autoradiography in Mfp2 -/- mice using the TSPO radiotracer [18F]DPA-714 confirmed increased expression of TSPO. These data demonstrate that TSPO imaging reveals microgliosis in non-neurodegenerative brain pathologies. CONCLUSIONS: We show that induced TSPO expression marks a pro-inflammatory brain environment that is not necessarily accompanied by neuronal loss.
PURPOSE: Activation of the innate immune system plays a significant role in pathologies of the central nervous system (CNS). In order to follow disease progression and evaluate effectiveness of potential treatments involved in neuroinflammation, it is important to track neuroinflammatory markers in vivo longitudinally. The translocator protein (TSPO) is used as a target to image neuroinflammation as its expression is upregulated in reactive glial cells during CNS pathologies. However, it remains unclear in which microglial phenotypes TSPO levels are upregulated, as microglia can display a plethora of activation states that can be protective or detrimental to the CNS. PROCEDURES: We assessed the levels of TSPO transcripts in cultured microglia that were polarized into pro- and anti-inflammatory states in vitro and in the brain of mice in which an anti-inflammatory environment was induced in vivo. In addition, we used a mouse model of peroxisomal multifunctional protein-2 (MFP2) deficiency that exhibits widespread neuroinflammation despite no neuronal loss and monitored TSPO expression by immunohistochemistry and by imaging using the TSPO radiotracer [18F]DPA-714. RESULTS:TSPO expression was selectively increased in so-called classically activated or M1 microglia but not in alternatively activated or M2 microglia in vitro. In agreement, TSPO transcript levels were not induced in an anti-inflammatory brain environment. We found that both transcript and protein levels of TSPO are significantly increased in the brain of Mfp2 -/- compared to those of the control mice and TSPO immunoreactivity colocalized predominantly with microglia in Mfp2 -/- brain. In vitro and ex vivo autoradiography in Mfp2 -/- mice using the TSPO radiotracer [18F]DPA-714 confirmed increased expression of TSPO. These data demonstrate that TSPO imaging reveals microgliosis in non-neurodegenerative brain pathologies. CONCLUSIONS: We show that induced TSPO expression marks a pro-inflammatory brain environment that is not necessarily accompanied by neuronal loss.
Entities:
Keywords:
Microglia; Mouse model; Neuroinflammation; PET tracer; Peroxisomes; TSPO
Authors: M Baes; S Huyghe; P Carmeliet; P E Declercq; D Collen; G P Mannaerts; P P Van Veldhoven Journal: J Biol Chem Date: 2000-05-26 Impact factor: 5.157
Authors: Rainer Rupprecht; Vassilios Papadopoulos; Gerhard Rammes; Thomas C Baghai; Jinjiang Fan; Nagaraju Akula; Ghislaine Groyer; David Adams; Michael Schumacher Journal: Nat Rev Drug Discov Date: 2010-12 Impact factor: 84.694
Authors: Cindy Casteels; Peter Vermaelen; Johan Nuyts; Annemie Van Der Linden; Veerle Baekelandt; Luc Mortelmans; Guy Bormans; Koen Van Laere Journal: J Nucl Med Date: 2006-11 Impact factor: 10.057
Authors: Simon Verheijden; Astrid Bottelbergs; Olga Krysko; Dmitri V Krysko; Lien Beckers; Stephanie De Munter; Paul P Van Veldhoven; Sabine Wyns; Wim Kulik; Klaus-Armin Nave; Matt S Ramer; Peter Carmeliet; Celia M Kassmann; Myriam Baes Journal: Neurobiol Dis Date: 2013-06-15 Impact factor: 5.996
Authors: Michael T Heneka; Monica J Carson; Joseph El Khoury; Gary E Landreth; Frederic Brosseron; Douglas L Feinstein; Andreas H Jacobs; Tony Wyss-Coray; Javier Vitorica; Richard M Ransohoff; Karl Herrup; Sally A Frautschy; Bente Finsen; Guy C Brown; Alexei Verkhratsky; Koji Yamanaka; Jari Koistinaho; Eicke Latz; Annett Halle; Gabor C Petzold; Terrence Town; Dave Morgan; Mari L Shinohara; V Hugh Perry; Clive Holmes; Nicolas G Bazan; David J Brooks; Stéphane Hunot; Bertrand Joseph; Nikolaus Deigendesch; Olga Garaschuk; Erik Boddeke; Charles A Dinarello; John C Breitner; Greg M Cole; Douglas T Golenbock; Markus P Kummer Journal: Lancet Neurol Date: 2015-04 Impact factor: 44.182
Authors: Regina Hummel; Sebastian Ulbrich; Dominik Appel; Shuailong Li; Tobias Hirnet; Sonja Zander; Wieslawa Bobkiewicz; Christina Gölz; Michael K E Schäfer Journal: Br J Pharmacol Date: 2020-10-23 Impact factor: 8.739
Authors: John Marshall; Jennifer B Nietupski; Hyejung Park; James Cao; Dinesh S Bangari; Cristina Silvescu; Terry Wilper; Kristen Randall; Drew Tietz; Bing Wang; Xiaoyou Ying; John P Leonard; Seng H Cheng Journal: Mol Ther Date: 2019-06-04 Impact factor: 11.454
Authors: Zeynab Alshelh; Daniel S Albrecht; Courtney Bergan; Oluwaseun Akeju; Daniel J Clauw; Lisa Conboy; Robert R Edwards; Minhae Kim; Yvonne C Lee; Ekaterina Protsenko; Vitaly Napadow; Kimberly Sullivan; Marco L Loggia Journal: Brain Behav Immun Date: 2020-02-04 Impact factor: 7.217
Authors: M Collins Scott; Supinder S Bedi; Scott D Olson; Candice M Sears; Charles S Cox Journal: Expert Opin Ther Targets Date: 2021-06-01 Impact factor: 6.902
Authors: Omkar L Patkar; Abdalla Z Mohamed; Ashwin Narayanan; Karine Mardon; Gary Cowin; Rajiv Bhalla; Damion H R Stimson; Michael Kassiou; Kate Beecher; Arnauld Belmer; Ignatius Alvarez Cooper; Michael Morgan; David A Hume; Katharine M Irvine; Selena E Bartlett; Fatima Nasrallah; Paul Cumming Journal: Sci Rep Date: 2021-05-27 Impact factor: 4.379